OmniAb, Inc. (OABI)
(Delayed Data from NSDQ)
$1.93 USD
-0.11 (-5.39%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.94 +0.01 (0.52%) 5:42 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OABI 1.93 -0.11(-5.39%)
Will OABI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OABI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OABI
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates
OABI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates
Other News for OABI
OmniAb GAAP EPS of -$0.15 in-line, revenue of $3.89M misses by $1.44M
OmniAb Inc Reports Q2 2025 Earnings: EPS Loss of $0. ...
Earnings Scheduled For August 6, 2025
OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights | OABI Stock News
OmniAb reports Q2 EPS (15c), consensus (15c)